Objective: To determine the serum levels of CMTM6 mRNA and CCN1 in patients with acute leukemia (AL), and to analyze their relationship with the clinical efficacy and prognosis of the patients.
Methods: 103 AL patients admitted to our hospital from February 2015 to January 2019 were included as the study subjects. Additionally, 100 healthy subjects who underwent physical examinations during the same period were included as the control group. qRT-PCR method was applied to detect the serum CMTM6 mRNA level of the study subjects, the serum CCN1 level was measured by ELISA. The levels of serum CMTM6 mRNA and CCN1 between the control group and AL patients, as well as between patients at initial diagnosis and after one course of chemotherapy were compared, the correlation of CMTM6 mRNA and CCN1 levels at initial diagnosis with clinicopathological features and short-term efficacy in AL patients was analyzed. The correlation of the CMTM6 mRNA and CCN1 expression levels with prognosis of the patients was analyzed by Kaplan-Meier curves.
Results: Compared with the control group, the serum CMTM6 mRNA level in AL patients was significantly increased (P < 0.05), while the serum CCN1 level was significantly decreased (P < 0.05). There were no statistically significant differences in serum CMTM6 mRNA and CCN1 levels between patients with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) (P >0.05). Compared with those at the initial diagnosis, both the serum CMTM6 mRNA and CNN1 expression levels in AL patients were significantly altered after one course of chemotherapy, with CMTM6 mRNA significantly decreased (P < 0.05) and CCN1 significantly increased (P < 0.05). The 3-year recurrence-free survival (RFS) rate was lower in the CMTM6 high expression group and the CCN1 low expression group, compared with the CMTM6 low expression group and CCN1 high expression group, respectively (P < 0.05).
Conclusion: Serum CMTM6 is highly expressed and CCN1 is lowly expressed in AL patients. The expression levels of serum CMTM6 and CCN1 are associated with the 3-year prognosis of the patients.
题目: 急性白血病患者血清CMTM6 、CCN1表达与临床疗效、预后的关系研究.
目的: 通过测定急性白血病（AL）患者血清中CMTM6 mRNA、CCN1水平，分析其与患者临床疗效以及预后的关系。.
方法: 选取2015年2月-2019年1月期间本院收治的103例AL患者作为研究对象，另选取同期健康体检者100例作为对照组，qRT-PCR法检测研究对象血清CMTM6 mRNA水平，ELISA法测定血清CCN1水平，比较对照组与AL患者、患者初诊时与化疗一个疗程后血清CMTM6 mRNA、CCN1水平，分析AL患者初诊时CMTM6 mRNA、CCN1水平与临床病理特征以及近期疗效的相关性，Kaplan-Meier曲线分析CMTM6 、CCN1表达水平与患者预后的关系。.
结果: 与对照组相比，AL患者血清CMTM6 mRNA水平明显升高（P < 0.05），血清CCN1水平明显下降（P < 0.05）；急性淋巴细胞白血病（ALL）与急性髓系白血病（AML）患者血清CMTM6 mRNA、CCN1水平差异无统计学意义（P >0.05）。与初诊时相比，化疗一个疗程后AL患者血清CMTM6 mRNA表达水平明显降低（P < 0.05），血清CCN1表达水平明显升高（P < 0.05）。CMTM6 高表达组、CCN1低表达组患者的3年无复发生存率分别低于CMTM6 低表达组和CCN1高表达组（P < 0.05）。.
结论: AL患者血清CMTM6 高表达、CCN1低表达，且二者的表达水平与患者3年预后相关。.
Keywords:
acute leukemia;